ImmuCell Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4525253062
USD
5.21
0.21 (4.2%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About ImmuCell Corp. stock-summary
stock-summary
ImmuCell Corp.
Pharmaceuticals & Biotechnology
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
Company Coordinates stock-summary
Company Details
56 Evergreen Dr , PORTLAND ME : 04103-1066
stock-summary
Tel: 1 207 8782770
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 6 Schemes (5.68%)

Foreign Institutions

Held by 3 Foreign Institutions (0.39%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. David Tomsche
Chairman of the Board
Mr. Michael Brigham
President, Chief Executive Officer, Treasurer, Secretary, Director
Ms. Bobbi Brockmann
Vice President - Sales and Marketing, Director
Mr. David Cunningham
Independent Director
Mr. Steven Rosgen
Independent Director
Mr. Jonathan Rothschild
Independent Director
Mr. Paul Wainman
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 60 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.14

stock-summary
Return on Equity

5.90%

stock-summary
Price to Book

2.00